Bavarian Nordic (XTRA:BV3) - Stock Price, News & Analysis

BV3 Stock Overview

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines.

BV3 fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	0/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 60.1% below our estimate of its fair value

Became profitable this year

Trading at good value compared to peers and industry

Risk Analysis

Earnings are forecast to decline by an average of 16.8% per year for the next 3 years

High level of non-cash earnings

Shares are highly illiquid

Shareholders have been diluted in the past year

Bavarian Nordic A/S Competitors

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€762.9m

2invest

XTRA:2INV

€49.7m

Dermapharm Holding

XTRA:DMP

€1.8b

Price History & Performance

Summary of all time highs, changes and price drops for Bavarian Nordic
Historical stock prices
Current Share Price	kr.25.30
52 Week High	kr.35.80
52 Week Low	kr.23.12
Beta	1.29
1 Month Change	0%
3 Month Change	-3.80%
1 Year Change	-12.61%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-58.71%

Recent updates

Shareholder Returns

	BV3	DE Biotechs	DE Market
7D	0%	2.1%	-1.0%
1Y	-12.6%	-22.2%	2.0%

Return vs Industry: BV3 exceeded the German Biotechs industry which returned -23.4% over the past year.

Return vs Market: BV3 underperformed the German Market which returned 4.7% over the past year.

Price Volatility

Is BV3's price volatile compared to industry and market?
BV3 volatility
BV3 Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.1%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.2%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: BV3 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine BV3's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1992	1,354	Paul Chaplin	www.bavarian-nordic.com

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers.

Bavarian Nordic A/S Fundamentals Summary

How do Bavarian Nordic's earnings and revenue compare to its market cap?
BV3 fundamental statistics
Market cap	€1.44b
Earnings (TTM)	€144.27m
Revenue (TTM)	€741.69m

10.0x

P/E Ratio

1.9x

P/S Ratio

Is BV3 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BV3 income statement (TTM)
Revenue	kr.5.53b
Cost of Revenue	kr.1.84b
Gross Profit	kr.3.69b
Other Expenses	kr.2.62b
Earnings	kr.1.08b

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Nov 16, 2023

Earnings per share (EPS)	13.84
Gross Margin	66.78%
Net Profit Margin	19.45%
Debt/Equity Ratio	0.2%

How did BV3 perform over the long term?

See historical performance and comparison

BV3 Stock Overview

Rewards

Risk Analysis

Bavarian Nordic A/S Competitors

XTRA:BIO3

€1.4b

XTRA:FYB

€762.9m

XTRA:2INV

€49.7m

XTRA:DMP

€1.8b

Price History & Performance

Recent News & Updates

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Recent updates

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold €68k worth of stock

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: kr.0.20 (vs kr.1.30 loss in 3Q 2021)

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Second quarter 2022 earnings released: kr.3.40 loss per share (vs kr.2.40 loss in 2Q 2021)

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022

First quarter 2022 earnings released

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of Its Covid-19 Booster Vaccine Candidate

Less than half of directors are independent

Bavarian Nordic Announces Initiation of A Global Phase 3 Clinical Trial of Its RSV Vaccine Candidate in Older Adults

Bavarian Nordic A/S Provides Revenue Guidance for the Full Year of 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Bavarian Nordic A/S Reports Additional Positive Phase 2 Results for Its Covid-19 Vaccine Candidate Ahead of Phase 3 Trial

Bavarian Nordic Announces Breakthrough Therapy Designation for Its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults

Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base

Bavarian Nordic A/S announced a financing transaction

Executive Officer Tommi Kainu has left the company

High number of new directors

Shareholder Returns

Price Volatility

About the Company

Bavarian Nordic A/S Fundamentals Summary

10.0x

1.9x

Earnings & Revenue